单位：[1]Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China北京朝阳医院[2]Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, No.17, Qi He Lou Street, Dongcheng District, Beijing, China[3]Department of Pharmacy, China-Japan Friendship Hospital, No.2 Yinghuayuan Dongjie, Chaoyang District, Beijing, China
第一作者单位：[1]Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China[2]Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, No.17, Qi He Lou Street, Dongcheng District, Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China[3]Department of Pharmacy, China-Japan Friendship Hospital, No.2 Yinghuayuan Dongjie, Chaoyang District, Beijing, China[*1]Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China[*2]Department of Pharmacy, Beijing Chao- Yang Hospital, Capital Medical University, Beijing, China.
推荐引用方式(GB/T 7714)：
Sun Ximu,Ma Zhuo,Guo Qixiang,et al.Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System[J].EUROPEAN JOURNAL of CANCER.2022,160:277-278.doi:10.1016/j.ejca.2021.10.034.
APA：
Sun Ximu,Ma Zhuo,Guo Qixiang,Zhao Zhixia&Liu Lihong.(2022).Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System.EUROPEAN JOURNAL of CANCER,160,
MLA：
Sun Ximu,et al."Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System".EUROPEAN JOURNAL of CANCER 160.(2022):277-278
医学